Clinical Trials Logo

Clinical Trial Summary

Background: Colorectal cancer is the most frequent neoplasm and the second cause of cancer death in Spain. Colon cleansing is critical for visualization of lesions at colonoscopy. High-quality cleansing allows for correct detection and resection of all lesions and may contribute to adequate risk stratification and follow-up interval. Low-volume laxatives improve tolerance of the colonoscopy preparation without reducing its effectiveness. Currently, the most widely used low-volume laxatives are one liter of Polyethylene glycol + ascorbate (PEG1A) and sodium picosulfate + magnesium citrate (PSCM). The evidence on the comparison of laxatives to achieve a high-quality colonic cleansing is very scarce. Hypothesis: Polyethylene glycol 1 liter with ascorbate is superior to sodium picosulfate and magnesium citrate in high-quality colon cleansing. Objective: Overall objective: To compare the global high-quality cleansing frequency between the two laxatives using the Harefield Scale (HS). The primary objective is to demonstrate non-inferiority in global high-quality cleansing of PEG1A compared to PSCM. If non-inferiority is demonstrated, superiority of PEG1A will be analyzed. Specific objectives: - Frequency of global high-quality cleansing using the Boston Bowel Preparation Scale (BBPS). - Frequency of adequate-quality cleansing using the HS and BBPS scales. - Tolerance and adverse effects of both laxatives. - Detection of lesions, total adenomas, advanced adenomas, total serrated lesions, advanced serrated lesions and colorectal cancer. - Detection of neoplastic lesions in the different colon segments (proximal, transverse, descending, sigmoid and rectum). - Association between detected lesions and the quality of the preparation, according to the HS and BBPS scales. Methods: Phase 4, multi-centric, randomized, single-blind (endoscopist), parallel study with two treatment arms: PEG1A (Pleinvue®) and PSCM (Citrafleet®).


Clinical Trial Description

This study will be performed in 1104 patients with a scheduled colonoscopy for any indication, who need a bowel preparation for the colonoscopy. Subjects will be randomly assigned to 1 of 2 treatment groups with a 1:1 allocation using block sizes of 6 cases in each center. The treatment assignment will be open to the participant and the physician. The investigator who performs the colonoscopy and assesses the primary outcome (digestive endoscopist) will be blinded. In both treatment groups, participants will receive instructions about colonoscopy preparation. Laxative treatment (PEG1A/PSCM) will be administered in two doses, at 9 pm on the day before intervention and 5 hours before colonoscopy, on an outpatient basis. The day of the colonoscopy appointment will be the final visit of the study. The participant will be asked through a questionnaire about adherence to instructions, tolerance and acceptability to the preparation, and the appearance of side effects. No follow-up period is considered after intervention. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04598880
Study type Interventional
Source Parc de Salut Mar
Contact Marco Antonio Alvarez González, MD, PhD
Phone +34932483057
Email MAAlvarez@parcdesalutmar.cat
Status Recruiting
Phase Phase 4
Start date November 6, 2020
Completion date May 2021

See also
  Status Clinical Trial Phase
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Terminated NCT01119027 - Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills N/A
Completed NCT01063231 - Evaluation of PillCamâ„¢ Colon 2 in Visualization of the Colon Phase 3
Completed NCT04074577 - Computer Aided Detection, Tandem Colonoscopy Study N/A
Not yet recruiting NCT04087824 - Deep Learning Algorithm for Recognition of Colonic Segments. N/A
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Terminated NCT02503631 - Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers
Completed NCT01600209 - Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing N/A
Completed NCT01260168 - Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies N/A
Completed NCT00604162 - PillCamâ„¢ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon Phase 3
Completed NCT01738425 - A Clinical Phase I Study on GIC-1001 in Healthy Volunteers Phase 1
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Completed NCT02291445 - Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study Phase 2
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03139942 - Optical Polyp Testing for In Vivo Classification N/A
Completed NCT04263818 - Endoscopist and Endoscope Motions During Colonoscopy N/A
Recruiting NCT05923918 - A Study to Evaluate Safety and Efficacy of PBK_M2101 Phase 3
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2
Completed NCT01397747 - Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer N/A